Journal article

Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia

  • Diop, Fary Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
  • Moia, Riccardo Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
  • Favini, Chiara Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
  • Spaccarotella, Elisa Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
  • De Paoli, Lorenzo Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
  • Bruscaggin, Alessio Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
  • Spina, Valeria Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
  • Terzi-di-Bergamo, Lodovico Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
  • Arruga, Francesca Department of Medical Sciences, University of Turin & Italian Institute for Genomic Medicine, Turin, Italy
  • Tarantelli, Chiara Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
  • Deambrogi, Clara Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
  • Rasi, Silvia Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
  • Adhinaveni, Ramesh Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
  • Patriarca, Andrea Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
  • Favini, Simone Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
  • Sagiraju, Sruthi Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
  • Jabangwe, Clive Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
  • Kodipad, Ahad A. Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
  • Peroni, Denise Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
  • Mauro, Francesca R. Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
  • Del Giudice, Ilaria Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
  • Forconi, Francesco Cancer Sciences Unit, Southampton Cancer Research UK and National Institute for Health Research Experimental Cancer Medicine Centre, University of Southampton, UK - Division of Hematology, University of Siena, Italy
  • Cortelezzi, Agostino Department of Hematology Oncology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico and University of Milan, Italy
  • Zaja, Francesco Clinica Ematologica, DAME, University of Udine, Italy
  • Bomben, Riccardo Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, Italy
  • Rossi, Francesca Maria Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, Italy
  • Visco, Carlo Department of Cell Therapy and Hematology, Ospedale San Bortolo, Vicenza, Italy
  • Chiarenza, Annalisa Division of Hematology, Azienda Ospedaliera Universitaria Policlinico-OVE, Catania, Italy
  • Rigolin, Gian Matteo Hematology Section, Azienda Ospedaliero Universitaria Arcispedale S. Anna, University of Ferrara, Italy
  • Marasca, Roberto Division of Hematology, Department of Oncology and Hematology, University of Modena and Reggio Emilia, Italy
  • Coscia, Marta Division of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza and University of Turin, Italy
  • Perbellini, Omar Section of Hematology, Department of Medicine, University of Verona, Italy
  • Tedeschi, Alessandra Department of Oncology/Haematology, Niguarda Cancer Center, Niguarda Ca Granda Hospital, Milan, Italy
  • Laurenti, Luca Fondazione Policlinico Universitario A. Gemelli, Rome, Italy
  • Motta, Marina Department of Hematology, Spedali Civili, Brescia, Italy
  • Donaldson, David Clinical Haematology, Belfast City Hospital, Belfast Health and Social Care Trust, Northern Ireland, UK
  • Weir, Phil Clinical Haematology, Belfast City Hospital, Belfast Health and Social Care Trust, Northern Ireland, UK
  • Mills, Ken Centre for Cancer Research and Cell Biology (CCRCB), Queen’s University Belfast, Northern Ireland, UK
  • Thornton, Patrick Department of Haematology, Beaumont Hospital, Dublin, Ireland
  • Lawless, Sarah Clinical Haematology, Belfast City Hospital, Belfast Health and Social Care Trust, Northern Ireland, UK
  • Bertoni, Francesco Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
  • Del Poeta, Giovanni Department of Hematology, Tor Vergata University, Rome, Italy
  • Cuneo, Antonio Hematology Section, Azienda Ospedaliero Universitaria Arcispedale S. Anna, University of Ferrara, Italy
  • Follenzi, Antonia Department of Health Sciences, University of Eastern Piedmont Amedeo Avogadro, Novara, Italy
  • Gattei, Valter Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, Italy
  • Boldorini, Renzo Luciano Department of Pathology, University of Eastern Piedmont Amedeo Avogadro, Novara, Italy
  • Catherwood, Mark Clinical Haematology, Belfast City Hospital, Belfast Health and Social Care Trust, Northern Ireland, UK
  • Deaglio, Silvia Department of Medical Sciences, University of Turin & Italian Institute for Genomic Medicine, Turin, Italy
  • Foà, Robin Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
  • Gaidano, Gianluca Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
  • Rossi, Davide Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
Show more…
    01.02.2020
Published in:
  • Haematologica. - 2020, vol. 105, no. 2, p. 448-456
English BIRC3 is a recurrently mutated gene in chronic lymphocytic leukemia (CLL) but the functional implications of BIRC3 mutations are largely unexplored. Furthermore, little is known about the prognostic impact of BIRC3 mutations in CLL cohorts homogeneously treated with first-line fludarabine, cyclophosphamide, and rituximab (FCR). By immunoblotting analysis, we showed that the non-canonical nuclear factor-κB pathway is active in BIRC3-mutated cell lines and in primary CLL samples, as documented by the stabilization of MAP3K14 and by the nuclear localization of p52. In addition, BIRC3-mutated primary CLL cells are less sensitive to flu-darabine. In order to confirm in patients that BIRC3 mutations confer resistance to fludarabine-based chemoimmunotherapy, a retrospective multicenter cohort of 287 untreated patients receiving first-line FCR was analyzed by targeted next-generation sequencing of 24 recurrently mutated genes in CLL. By univariate analysis adjusted for multiple comparisons BIRC3 mutations identify a poor prognostic subgroup of patients in whom FCR treatment fails (median progression-free survival: 2.2 years, P<0.001) similar to cases harboring TP53 mutations (median progression-free survival: 2.6 years, P<0.0001). BIRC3 mutations maintained an independent association with an increased risk of progression with a hazard ratio of 2.8 (95% confidence interval 1.4-5.6, P=0.004) in multivariate analysis adjusted for TP53 mutation, 17p deletion and IGHV mutation status. If validated, BIRC3 mutations may be used as a new molecular predictor to select high-risk patients for novel frontline therapeutic approaches.
Language
  • English
Classification
Medicine
License
License undefined
Identifiers
Persistent URL
https://susi.usi.ch/usi/documents/319160
Statistics

Document views: 27 File downloads:
  • Rossi_2020_haematologica.pdf: 3